Ian R. Rifkin, MD, PhD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Nephrology

MBBCh, University of the Witwatersrand
PhD, University of Cambridge
MSc, University of London




Expertise includes: Immunology; Autoimmunity; Systemic lupus erythematosus; and Nephrology.

Assistant Professor
Boston University School of Medicine
Microbiology


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




Tool-like receptors in Systemic Autoimmune Disease
02/11/2010 - 06/30/2014 (Subcontract PI)
University of Massachusetts, Worcester NIH NIAMS
5P01AR050256-11

Role of Toll-like Receptors in Dendritic Cell Activation by Chromatin-Containing Immune Complexes
08/01/2002 - 01/31/2007 (PI)
The Lupus Research Institute Inc

Toll-like Receptors in the Pathogenesis of SLE and Immunologically-Mediated Renal Disease
04/01/2002 - 12/31/2006 (Co-PI)
Coley Pharmaceutical Group


Dr. Rifkin _ Sanofi
04/20/2020 - 04/19/2023 (PI)
Sanofi US Services Inc Sanofi US Services Inc

The Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLE
09/22/2017 - 08/31/2022 (PI)
NIH-NIAID
5R01AI130199-02

Evaluation of gene expression at the single cell level in kidney biopsies and urine from patients…
07/01/2020 - 06/30/2021 (PI)
Chugai Pharmaceutical, Co., Ltd.

Research Training in Nephrology
07/01/2015 - 06/30/2020 (PI)
NIH-NIDDK
5T32DK007053-46

Immunomodulator identification in systemic lupus erythematosus
12/02/2015 - 06/01/2020 (PI)
Merck

The role of innate immune system mediators and pathways in SLE pathogenesis
12/21/2015 - 12/20/2018 (PI)
Merck

Evaluation of antibodies for the treatment of autoimmune diseases
03/01/2016 - 04/30/2018 (PI)
Chugai Pharmaceutical, Co., Ltd.

Evaluating impact of Biogen IRAK 4 inhibitors on metabolism and generation of human plasmacytoid den
09/23/2013 - 09/30/2016 (PI)
Biogen, Inc

SLE-immune complex-mediated inflammatory cell activation: regulation by IRF5 and new effector discov
11/01/2012 - 08/31/2015 (PI)
Kyowa Hakko Kirin Co.

IRAK4 Kinase and Autoimmune Disease
10/01/2011 - 09/30/2013 (PI)
Biogen, Inc

Showing 10 of 16 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs
2020 The Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLE 5R01AI130199-04
2019 The Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLE 5R01AI130199-03
2019 Research Training in Nephrology 5T32DK007053-46 48
2018 The Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLE 5R01AI130199-02
2018 Research Training in Nephrology 5T32DK007053-45 48
2018 Research Training in Nephrology 3T32DK007053-45S1 48
2017 The Role of Interferon Regulatory Factor 5 in the Pathogenesis of SLE 1R01AI130199-01A1
2017 Research Training in Nephrology 5T32DK007053-44 48
2013 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-11-6674 66
2012 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-10-6674 66
Showing 10 of 26 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Pellerin A, Yasuda K, Cohen-Bucay A, Sandra V, Shukla P, Jr BKH, Nündel K, Viglianti GA, Xie Y, Klein U, Tan Y, Bonegio RG, Rifkin IR. Monoallelic IRF5 deficiency in B cells prevents murine lupus. JCI Insight. 2021 Aug 09; 6(15).View Related Profiles. PMID: 34197340
     
  2. Yuen RR, Steiner D, Pihl RMF, Chavez E, Olson A, Smith EL, Baird LA, Korkmaz F, Urick P, Sagar M, Berrigan JL, Gummuluru S, Corley RB, Quillen K, Belkina AC, Mostoslavsky G, Rifkin IR, Kataria Y, Cappione AJ, Gao W, Lin NH, Bhadelia N, Snyder-Cappione JE. Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Front Immunol. 2021; 12:614676.View Related Profiles. PMID: 33897682; PMCID: PMC8062931; DOI: 10.3389/fimmu.2021.614676;
     
  3. Lee J, Zhang J, Chung YJ, Kim JH, Kook CM, González-Navajas JM, Herdman DS, Nürnberg B, Insel PA, Corr M, Mo JH, Tao A, Yasuda K, Rifkin IR, Broide DH, Sciammas R, Webster NJ, Raz E. Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. Elife. 2020 02 04; 9.View Related Profiles. PMID: 32014112; PMCID: PMC7000221; DOI: 10.7554/eLife.49416;
     
  4. Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, Belghasem M, Vellard I, Yin W, Ravid JD, Zavaro E, Amraei R, Francis J, Phatak U, Rifkin IR, Rahimi N, Chitalia VC. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257.View Related Profiles. PMID: 31882749; PMCID: PMC6934810; DOI: 10.1038/s41598-019-56208-1;
     
  5. Rifkin IR, Bonegio RG. Editorial: Podocytes as Active Participants in Lupus Nephritis. Arthritis Rheumatol. 2017 08; 69(8):1517-1520.View Related Profiles. PMID: 28544537
     
  6. Choo MK, Sano Y, Kim C, Yasuda K, Li XD, Lin X, Stenzel-Poore M, Alexopoulou L, Ghosh S, Latz E, Rifkin IR, Chen ZJ, Stewart GC, Chong H, Park JM. TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects. J Exp Med. 2017 May 01; 214(5):1297-1311.View Related Profiles. PMID: 28400473; PMCID: PMC5413331; DOI: 10.1084/jem.20161141;
     
  7. Das A, Heesters BA, Bialas A, O'Flynn J, Rifkin IR, Ochando J, Mittereder N, Carlesso G, Herbst R, Carroll MC. Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses. Immunity. 2017 Jan 17; 46(1):106-119. PMID: 28099860; PMCID: PMC8140609; DOI: 10.1016/j.immuni.2016.12.014;
     
  8. Duffau P, Menn-Josephy H, Cuda CM, Dominguez S, Aprahamian TR, Watkins AA, Yasuda K, Monach P, Lafyatis R, Rice LM, Kenneth Haines G, Gravallese EM, Baum R, Richez C, Perlman H, Bonegio RG, Rifkin IR. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 2015 Dec; 67(12):3146-57.View Related Profiles. PMID: 26315890; PMCID: PMC4661118; DOI: 10.1002/art.39321;
     
  9. Aprahamian TR, Zhong X, Amir S, Binder CJ, Chiang LK, Al-Riyami L, Gharakhanian R, Harnett MM, Harnett W, Rifkin IR. The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. Int J Parasitol. 2015 Mar; 45(4):203-7.View Related Profiles. PMID: 25666929; PMCID: PMC4355381; DOI: 10.1016/j.ijpara.2014.12.006;
     
  10. Watkins AA, Yasuda K, Wilson GE, Aprahamian T, Xie Y, Maganto-Garcia E, Shukla P, Oberlander L, Laskow B, Menn-Josephy H, Wu Y, Duffau P, Fried SK, Lichtman AH, Bonegio RG, Rifkin IR. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J Immunol. 2015 Feb 15; 194(4):1467-79.View Related Profiles. PMID: 25595782; PMCID: PMC4323680; DOI: 10.4049/jimmunol.1402807;
     
Showing 10 of 56 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 56 publications over 25 distinct years, with a maximum of 6 publications in 2009

YearPublications
19871
19911
19922
19932
19941
19951
19961
19981
19991
20002
20021
20032
20044
20052
20065
20072
20096
20103
20132
20144
20155
20173
20191
20201
20212

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

atherosclerosis
Autoimmunity
interferon regulatory factors
systemic lupus erythematosus
Toll like receptors
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Rifkin's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department